These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36759855)

  • 1. Need for integration of hepatitis C (HCV) services in community-based settings for people who inject drugs: results from a global values and preferences survey.
    Di Ciaccio M; Villes V; Perfect C; El Kaim JL; Donatelli M; James C; Easterbrook P; Delabre RM
    Harm Reduct J; 2023 Feb; 20(1):15. PubMed ID: 36759855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review.
    Hajarizadeh B; Kairouz A; Ottaviano S; Ireland J; Willing A; Cunningham E; Webb P; Colledge-Frisby S; Wheeler A; Leung J; Tran LT; Price O; Vickerman P; Farrell M; Hickman M; Dore GJ; Bergenström A; Degenhardt L; Grebely J
    Lancet Glob Health; 2023 Dec; 11(12):e1885-e1898. PubMed ID: 37973339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis.
    Oru E; Trickey A; Shirali R; Kanters S; Easterbrook P
    Lancet Glob Health; 2021 Apr; 9(4):e431-e445. PubMed ID: 33639097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated supervised consumption services and hepatitis C testing and treatment among people who inject drugs in Toronto, Canada: A cross-sectional analysis.
    Greenwald ZR; Bouck Z; McLean E; Mason K; Lettner B; Broad J; Dodd Z; Nassau T; Scheim AI; Werb D
    J Viral Hepat; 2023 Feb; 30(2):160-171. PubMed ID: 36461705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs - a scoping review of the qualitative evidence.
    Balsom CR; Farrell A; Kelly DV
    BMC Public Health; 2023 Jun; 23(1):1038. PubMed ID: 37259073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland: A quantitative cross-sectional analysis.
    Yuan JM; Croxford S; Viviani L; Emanuel E; Phipps E; Desai M
    Int J Drug Policy; 2022 Nov; 109():103821. PubMed ID: 35994940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
    Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
    Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of direct and indirect social and spatial ties in the diffusion of HIV and HCV among people who inject drugs: a cross-sectional community-based network analysis in New Delhi, India.
    Clipman SJ; Mehta SH; Srikrishnan AK; Zook KJ; Duggal P; Mohapatra S; Shanmugam S; Nandagopal P; Kumar MS; Ogburn E; Lucas GM; Latkin CA; Solomon SS
    Elife; 2021 Aug; 10():. PubMed ID: 34342266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada.
    Broad J; Mason K; Guyton M; Lettner B; Matelski J; Powis J
    Int J Drug Policy; 2020 Jun; 80():102755. PubMed ID: 32416538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Values and preferences for hepatitis C self-testing among people who inject drugs in Kyrgyzstan.
    Martínez-Pérez GZ; Nikitin DS; Bessonova A; Fajardo E; Bessonov S; Shilton S
    BMC Infect Dis; 2021 Jun; 21(1):609. PubMed ID: 34171990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to HIV and Hepatitis C care for people who inject drugs in Colombia.
    Borda JP; Friedman HL; Castaño GA; Rodríguez HA; Muñoz CF; Tofighi B
    AIDS Care; 2022 May; 34(5):633-638. PubMed ID: 33615915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C antibody prevalence, correlates and barriers to care among people who inject drugs in Central California.
    Ozga JE; Syvertsen JL; Pollini RA
    J Viral Hepat; 2022 Jul; 29(7):518-528. PubMed ID: 35357738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 1: Critical hepatitis C and injector data.
    Bird SM; Goldberg DJ; Hutchinson SJ
    J Epidemiol Biostat; 2001; 6(3):243-65; discussion 279-85. PubMed ID: 11437088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia.
    Bajis S; Maher L; Treloar C; Hajarizadeh B; Lamoury FMJ; Mowat Y; Schulz M; Marshall AD; Cunningham EB; Cock V; Ezard N; Gorton C; Hayllar J; Smith J; Whelan M; Martinello M; Applegate TL; Dore GJ; Grebely J;
    Int J Drug Policy; 2018 Nov; 61():23-30. PubMed ID: 30388566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study.
    Valerio H; Conway A; Alavi M; Treloar C; Silk D; Murray C; Henderson C; Amin J; Read P; Degenhardt L; Christmass M; Montebello M; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Dec; 110():103876. PubMed ID: 36240657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non-rural communities.
    Barranco MA; Rosenberg ES; Flanigan C; Shufelt S; Bruce EM; Wilberschied LA; Parker MM; Duncan E; Udo T
    J Viral Hepat; 2022 Nov; 29(11):994-1003. PubMed ID: 35925950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus risk among young people who inject drugs.
    Mateu-Gelabert P; Sabounchi NS; Guarino H; Ciervo C; Joseph K; Eckhardt BJ; Fong C; Kapadia SN; Huang TTK
    Front Public Health; 2022; 10():835836. PubMed ID: 35968435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
    Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
    Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.